(Bit­te bis zum Ende ansehen!)

Incl. COVID 19 IMPFUNG durch die NASE von Firma ALTIMMUNE + Mein CO2 Konzentrations-Test an 5 Masken (Bitte bis zum Ende ansehen!)

https://www.youtube.com/watch?v=lbCrPK0qLQg

Weitere Corona-Hilfen: Altimmune mit starkem Kursplus 

Redaktion Börse Global — 9. Juli 2020

Das Unter­neh­men Altim­mu­ne kann noch ein­mal die ges­tern voll­zo­ge­ne Kurs­ral­lye fort­set­zen. Die Titel notie­ren an der Wall Street mit einem Kurs­plus von 38 Pro­zent bei über 23 US-Dol­lar. Damit hat das Unter­neh­men mehr als 1.000 Pro­zent seit Ende Janu­ar zuge­legt. Damals notier­te das Unter­neh­men noch unter 2 Dol­lar! Was war der Hin­ter­grund der aktu­el­len Kursrallye?Altimmune hat mit der Dyn­Port Vac­ci­ne Com­pa­ny eine Ver­ein­ba­rung getrof­fen, die den Erhalt von offi­zi­el­len Gel­dern zur Finan­zie­rung ihrer Impf­stoff­ent­wick­lung gegen Covid19 zur Grund­la­ge hat.

Altimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID™ Clinical Trial

Email Print Friendly Share

December 23, 2020 16:01 ET | Source: Altimmune, Inc. GAITHERSBURG, Md., Dec. 23, 2020 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a clinical hold on the Company’s Investigational New Drug (IND) application for AdCOVID, a single-dose intranasal COVID-19 vaccine candidate. The Agency requested certain protocol modifications and the submission of additional Chemistry, Manufacturing and Controls (CMC) data. Altimmune has responded to the Agency’s clinical hold letter received on December 22, 2020 and, at this time, does not anticipate a significant impact on the overall clinical development timeline as the Company has agreed to each of the FDA’s requests. “We appreciate the FDA’s support and guidance as we seek to bring a novel, single-dose intranasal COVID-19 vaccine candidate into the clinic,” said Vipin K. Garg, President and Chief Executive Officer of Altimmune. “We look forward to working with the FDA and will continue preparing to commence our planned Phase 1 clinical trial of AdCOVID.” About AdCOVID AdCOVID is a single-dose intranasal COVID-19 vaccine candidate developed by Altimmune based on the Company’s significant experience in the development of intranasal vaccines for respiratory pathogens. In recently published preclinical studies (www.biorxiv.org/content/10.1101/2020.10.10.331348v1)

Altimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID™ Clinical Trial